Across TCGA pan-cancer cohorts, COL6A5 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated COL6A5 data layer compared with 28 for mass-spec protein and 5 for mutation status.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher COL6A5 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated COL6A5 expression acts as an unfavorable survival marker.
COAD are the cancer types where COL6A5 mass-spec protein most reproducibly stratifies survival.